Oxybuprocaine

Oxybuprocaine
Systematic (IUPAC) name
2-diethylaminoethyl 4-amino-3-butoxy-benzoate
Clinical data
Trade names Novesin(e)
AHFS/Drugs.com International Drug Names
  • AU: D
Topical
Pharmacokinetic data
Metabolism Esterases in blood plasma and liver
Identifiers
99-43-4 Yes
D04AB03 S01HA02
PubChem CID 4633
DrugBank DB00892 Yes
ChemSpider 4472 Yes
UNII AXQ0JYM303 Yes
KEGG D08319 Yes
ChEBI CHEBI:309594 Yes
ChEMBL CHEMBL1200 Yes
Chemical data
Formula C17H28N2O3
308.41 g/mol
 Yes (what is this?)  (verify)

Oxybuprocaine (INN), also known as benoxinate or BNX, is an ester-type local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.

Safety for use in pregnancy and lactation has not been established.

Uses

Pharmacokinetics

Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on perfusion. The drug is metabolised by esterases in blood plasma and liver.[2]

Adverse effects

When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example tetracaine, proxymetacaine and proparacaine) can cause irritation, hypersensitivity, anaphylaxis, irreversible corneal damage and even complete destruction of the cornea.[1][3] (Excessive use means several times a day during several days or even weeks.)

Interactions

Oxybuprocaine is incompatible with silver and mercury salts, as well as basic substances. It also reduces the antimicrobial action of sulfonamides.[2]

See also

References

  1. 1.0 1.1 Drugs.com: Minims Oxybuprocaine Hydrochloride 0.4%
  2. 2.0 2.1 2.2 2.3 2.4 Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
  3. McGee, H. T.; Fraunfelder, F. W. (2007). "Toxicities of topical ophthalmic anesthetics". Expert Opinion on Drug Safety 6 (6): 637–640. doi:10.1517/14740338.6.6.637. PMID 17967152.